|Bid||5.03 x 0|
|Ask||5.05 x 0|
|Day's Range||4.88 - 5.09|
|52 Week Range||3.70 - 9.29|
|Beta (3Y Monthly)||2.92|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.95|
HEXO Corp. (TSX:HEXO) has been a relatively steady stock in 2018. Are big gains on the way next year?
The Quebec-based producer reported $6.7 million in revenue during the three-months ended Oct. 31, up from $1.1 million of medical pot sales during the same period a year ago. The bulk of the revenue during the first quarter of its 2019 financial year came from recreational pot after Canada legalized it on Oct. 17, with 90 per cent of the sales generated in Quebec and 10 per cent in Ontario and British Columbia.
Following Altria’s news, Cronos Group (CRON) received target price upgrades from notable investment management companies. On average, four companies (MJ) upgraded Cronos Group’s target price by nearly 70%.
HEXO Corp. (HEXO.TO) (the "Company") is reporting its financial results for the first quarter of the 2019 fiscal year. Gross revenue for the quarter reached $6.7 million, which includes $5.2 million in sales of adult-use cannabis in the first two weeks following legalization in Canada. “HEXO hit tremendous milestones in the weeks following the legalization of adult-use cannabis,” said HEXO’s CEO and co-founder Sebastien St-Louis.
In the previous part, we discussed that nine major cannabis stocks’ (HMMJ) forward EV-to-EBITDA multiples declined nearly 26% on average to 14.9x month-over-month.
Earlier in this series, we discussed how the average forward EV-to-sales multiple of nine Canadian cannabis (MJ) stocks were trading at an all-time low of 4.6x. Let’s look at each of the nine cannabis stocks that are part of the average multiple below.
Hexo Corp. (TSX:HEXO) offers a strong portfolio of domestic products and forged agreements that more than counters its peers who are focused on other markets.
Why I still believe Hexo Corp. (TSX:HEXO) is an acquisition target, and why Bay Street may agree with this assessment.
Earlier in November, Senate Majority Leader Mitch McConnell indicated a provision for hemp legalization in the latest version of the farm bill. The provision will include making hemp a legal agricultural commodity in the United States. Hemp can be used to make CBD derivative products that don’t have exposure like other marijuana products including THC, a psychoactive ingredient, that makes it a controlled substance.
GATINEAU, Quebec, Nov. 30, 2018 -- HEXO Corp (“HEXO” or the “Company”) (TSX:HEXO) was honoured for product innovation with two prestigious Canadian Cannabis Awards at the 2018.
On November 29, Jim Cramer, the widely followed host of Mad Money on CNBC, reiterated his confidence in the cannabis industry. He recommended Constellation Brands as one of his four top picks. Cramer’s main reasons for recommending Constellation Brands stemmed from its investment in Canopy Growth (WEED)—the cannabis giant in Canada.
POINT ROBERTS, Wash., Nov. 29, 2018 -- Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks releases a sector snapshot with a.
Canopy Growth Corp (TSX:WEED)(NYSE:CGC) has done well over the past few years, but it may have finally run out of steam.
Curaleaf Holdings (LDVTF) has entered into a few agreements for the expansion of its presence, and it’s also achieved a few milestones this year. We’ll discuss some of the company’s key developments in 2018 in this article.
Aphria (TSX:APHA) (NYSE:APHA) and HEXO (TSX:HEXO) are down from the 2018 highs. Is this the time to buy?
The overall market has been weak in November. Global trade tension remains on edge, while oil prices have experienced a downward slide. In Canada, three sectors managed to remain in the positive territory, while the cannabis sector was largely in the negative territory.
This ETF focuses on North American publicly listed life sciences companies with significant business in the cannabis industry. The fund has operated since April 2017, and its market capitalization is 785.9 million Canadian dollars as of November 26. The price decreased ~2.9% last week and ~4.6% in 2018 year-to-date to a closing price of 18.05 Canadian dollars on November 23. ETFMG Alternative Harvest ETF (MJ)
Aurora Cannabis (TSX:ACB) (NYSE:ACB) and HEXO (TSX:HEXO) are down from their 2018 highs. Is one a buy?
HEXO Corp. (TSX:HEXO) and Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) are supplying the cannabis-infused beverage kings. Here's why both stocks could skyrocket like a bat out of hell.
In this part, we’ll discuss how the nine cannabis stocks’ (MJ) forward EV-to-EBITDA multiples have changed month-over-month. From the above chart, you can see that most of the cannabis stocks are trading at a discount compared to their multiples in October. Aurora Cannabis (ACB) was trading at a multiple of 26.4x, which declined from 34x in October.
Earlier in this series, we saw how cannabis stocks’ (HMMJ) forward EV-to-sales multiples were testing the lower resistance level. Investors usually use more than one multiple to determine the value of investments. In this case, we’ll use the forward EV-to-EBITDA multiple.
HEXO (HEXO) has been a strong cannabis player in Canada and its joint venture with Molson Coors makes it one of only two companies to have a partnership with an alcoholic beverage company. Canopy Growth (WEED), who has partnered with Constellation Brands, is the second company. HEXO is also one of the best performers (MJ) so far this year with a YTD return of nearly 30%.
Aphria (APHQF) has had one of the weakest months compared to other cannabis companies (HMMJ) such as Canopy Growth (WEED), Supreme Cannabis (SPRWF), and HEXO (HEXO). In this month alone, the stock has declined by nearly 21.4%. Let’s look at what analysts think.